Page 97 - புனே அடிப்படையிலானது சீரம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Serum Institute of India writes to PMO proposing reforms in drug regulatory system India Updated: Thursday, March 4, 2021, 21:28 [IST] New Delhi, Mar 04: The world s largest vaccine manufacturer by volume, Serum Institute of India, has written to the Prime Minister s Office proposing reforms in the existing drug regulatory system, including allowing manufacturing and stockpiling of non-COVID vaccines while undergoing clinical trial. In the letter, Prakash Kumar Singh, the Director of Government and Regulatory Affairs at the Pune-based Serum Institute of India (SII) referred to the Health Ministry s May 18, 2020, gazette notification, saying it allowed manufacturing and stockpiling of COVID-19 vaccine under clinical trial for marketing authorization for sale or distribution.

New delhiPrakash kumar singhNarendra modiMadhuri adnalSimran kashyapRajesh bhushanRegulatory affairsSerum institute of indiaHealth ministrySerum institutePrime ministerPune based serum instituteDrugs controller generalDrug regulatory systemsPrime minister narendra modiDrug regulatory